These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23837139)

  • 1. Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients.
    Lee HS; Kweon YO; Tak WY; Park SY; Kang EJ; Lee YL; Yang HM; Park HW
    Clin Mol Hepatol; 2013 Jun; 19(2):148-55. PubMed ID: 23837139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.
    Kim KH; Jang BK; Chung WJ; Hwang JS; Kweon YO; Tak WY; Lee HJ; Lee CH; Suh JI
    Korean J Hepatol; 2011 Sep; 17(3):220-5. PubMed ID: 22102389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
    Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
    Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
    Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
    Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Iio S; Oshita M; Hagiwara H; Mita E; Inui Y; Hijioka T; Inada M; Tamura S; Yoshihara H; Inoue A; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Hayashi N; Takehara T
    J Gastroenterol; 2014 Apr; 49(4):737-47. PubMed ID: 23689988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
    Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
    World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.
    Parise ER; de Oliveira AC; Conceição RD; Amaral AC; Leite K
    Braz J Infect Dis; 2006 Apr; 10(2):78-81. PubMed ID: 16878256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.
    Valenti L; Aghemo A; Stättermayer AF; Maggioni P; De Nicola S; Motta BM; Rumi MG; Dongiovanni P; Ferenci P; Colombo M; Fargion S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1434-42. PubMed ID: 22530607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C.
    Yu JW; Sun LJ; Kang P; Yan BZ; Zhao YH
    Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):185-92. PubMed ID: 22484588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients.
    Kim YJ; Jang BK; Kim ES; Park KS; Cho KB; Chung WJ; Hwang JS
    Korean J Hepatol; 2012 Mar; 18(1):41-7. PubMed ID: 22511902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
    Hu CC; Lin CL; Chang LC; Chien CH; Chen LW; Liu CJ; Chien RN
    BMC Infect Dis; 2015 Mar; 15():156. PubMed ID: 25888020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Int J Infect Dis; 2011 Nov; 15(11):e740-6. PubMed ID: 21803628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
    Méndez-Navarro J; Chirino RA; Corey KE; Gorospe EC; Zheng H; Morán S; Juarez JA; Chung RT; Dehesa-Violante M
    Dig Dis Sci; 2010 Sep; 55(9):2629-35. PubMed ID: 19960257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
    Lee JE; Yoon NR; Kim JD; Song MJ; Kwon JH; Bae SH; Choi JY; Jeong SW; Yoon SK
    Korean J Gastroenterol; 2011 Mar; 57(3):173-9. PubMed ID: 21519165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
    Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
    Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.